Back to listings
Patent
CRISPR-Cas9 Base Editing Patent Portfolio
GenomicPath SciencesListed Mar 9, 2026
Description
A comprehensive portfolio of 12 granted US patents covering novel base editing methods using CRISPR-Cas9 derivatives. The portfolio includes methods for precise adenine-to-inosine editing in mammalian cells, with applications in genetic disease correction. Clinical efficacy demonstrated in sickle cell disease models with >95% on-target editing efficiency.
Tags
CRISPRgene editingrare diseasesickle cell
Technical Details
- Patent Number
- US10,982,210
- Patent Status
- Granted
Asking Price
$8,500,000
About the Seller
Dr. Sarah Mitchell
GenomicPath Sciences
CRISPR researcher with 15+ years in gene editing and patent development.